China

If approved and launched, the vaccine will complement CanSinoBIO’s recently approved three-component DTaP vaccine, Tripecia® (DT3cP Infant), expanding the company’s pertussis-containing vaccine portfolio across age groups.

The latest approval expands the clinical use of ivonescimab in China and follows previous NMPA authorisations for regimens containing the molecule.

Vanflyta received approval in China in June 2026 for use in adults with newly diagnosed FLT3-ITD-positive AML, as determined by an appropriate validated diagnostic test.

The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.

AsymBio plans to use the additional capital to expand its research and development capabilities, GMP manufacturing lines and high-containment facilities.

Under the collaboration, Chugai scientists will use Biomni Lab to bring together AI capabilities and diverse biomedical resources within the company’s research environment.

IMPACT Therapeutics received approval from China’s National Medical Products Administration (NMPA) in January 2025 for senaparib as a first-line maintenance therapy for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer.

MindRank developed MAP as an AI-native drug discovery engine that combines computational biology, chemistry, laboratory experiments and clinical data into a single research platform.

Under the agreement, Everest Medicines will receive US$112.5 million upfront from Travere Therapeutics and could earn up to US$1.03 billion more in milestone payments if certain clinical, regulatory, and commercial goals are met across five indications.